BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29566836)

  • 1. Resource Use and Cost of Alzheimer's Disease in France: 18-Month Results from the GERAS Observational Study.
    Rapp T; Andrieu S; Chartier F; Deberdt W; Reed C; Belger M; Vellas B
    Value Health; 2018 Mar; 21(3):295-303. PubMed ID: 29566836
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and Resource Use Associated with Alzheimer's Disease in Italy: Results from an Observational Study.
    Bruno G; Mancini M; Bruti G; Dell'Agnello G; Reed C
    J Prev Alzheimers Dis; 2018; 5(1):55-64. PubMed ID: 29405234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resource utilisation, costs and clinical outcomes in non-institutionalised patients with Alzheimer's disease: 18-month UK results from the GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2016 Nov; 16(1):195. PubMed ID: 27887645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The GERAS Study: a prospective observational study of costs and resource use in community dwellers with Alzheimer's disease in three European countries--study design and baseline findings.
    Wimo A; Reed CC; Dodel R; Belger M; Jones RW; Happich M; Argimon JM; Bruno G; Novick D; Vellas B; Haro JM
    J Alzheimers Dis; 2013; 36(2):385-99. PubMed ID: 23629588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and quality of life in community-dwelling patients with Alzheimer's disease in Spain: results from the GERAS II observational study.
    Olazarán J; Agüera-Ortiz L; Argimón JM; Reed C; Ciudad A; Andrade P; Dilla T
    Int Psychogeriatr; 2017 Dec; 29(12):2081-2093. PubMed ID: 28720158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Costs and Resource Use Associated with Community-Dwelling Patients with Alzheimer's Disease in Japan: Baseline Results from the Prospective Observational GERAS-J Study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Treuer T; Sato M; Kahle-Wrobleski K; Meguro K; Yamada M; Mimura M; Arai H
    J Alzheimers Dis; 2020; 74(1):127-138. PubMed ID: 31985460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dependence Levels as Interim Clinical Milestones Along the Continuum of Alzheimer's Disease: 18-Month Results from the GERAS Observational Study.
    Kahle-Wrobleski K; Andrews JS; Belger M; Ye W; Gauthier S; Rentz DM; Galasko D
    J Prev Alzheimers Dis; 2017; 4(2):72-80. PubMed ID: 29186278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costs and resource use of community-dwelling patients with Alzheimer's disease in Japan: 18-month results from the GERAS-J study.
    Nakanishi M; Igarashi A; Ueda K; Brnabic AJM; Matsumura T; Meguro K; Yamada M; Mimura M; Arai H; Treuer T
    Curr Med Res Opin; 2021 Aug; 37(8):1331-1339. PubMed ID: 33904362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What Drives Country Differences in Cost of Alzheimer's Disease? An Explanation from Resource Use in the GERAS Study.
    Reed C; Happich M; Argimon JM; Haro JM; Wimo A; Bruno G; Dodel R; Jones RW; Vellas B; Belger M
    J Alzheimers Dis; 2017; 57(3):797-812. PubMed ID: 28304285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying factors of activities of daily living important for cost and caregiver outcomes in Alzheimer's disease.
    Reed C; Belger M; Vellas B; Andrews JS; Argimon JM; Bruno G; Dodel R; Jones RW; Wimo A; Haro JM
    Int Psychogeriatr; 2016 Feb; 28(2):247-59. PubMed ID: 26307191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors associated with long-term impact on informal caregivers during Alzheimer's disease dementia progression: 36-month results from GERAS.
    Reed C; Belger M; Scott Andrews J; Tockhorn-Heidenreich A; Jones RW; Wimo A; Dodel R; Haro JM
    Int Psychogeriatr; 2020 Feb; 32(2):267-277. PubMed ID: 31134870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of time to institutionalisation and related healthcare and societal costs in a community-based cohort of patients with Alzheimer's disease dementia.
    Belger M; Haro JM; Reed C; Happich M; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    Eur J Health Econ; 2019 Apr; 20(3):343-355. PubMed ID: 30178148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results.
    Dodel R; Belger M; Reed C; Wimo A; Jones RW; Happich M; Argimon JM; Bruno G; Vellas B; Haro JM
    Alzheimers Dement; 2015 Aug; 11(8):933-45. PubMed ID: 25846298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
    Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
    BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1.
    Robinson RL; Rentz DM; Andrews JS; Zagar A; Kim Y; Bruemmer V; Schwartz RL; Ye W; Fillit HM
    J Alzheimers Dis; 2020; 75(2):437-450. PubMed ID: 32250304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of diabetes on caregiver burden in an observational study of individuals with Alzheimer's disease.
    Lebrec J; Ascher-Svanum H; Chen YF; Reed C; Kahle-Wrobleski K; Hake AM; Raskin J; Naderali E; Schuster D; Heine RJ; Kendall DM
    BMC Geriatr; 2016 May; 16():93. PubMed ID: 27142529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of full costs of care for patients with Alzheimer's disease in France: the predominant role of informal care.
    Gervès C; Chauvin P; Bellanger MM
    Health Policy; 2014 May; 116(1):114-22. PubMed ID: 24461717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to deal with missing longitudinal data in cost of illness analysis in Alzheimer's disease-suggestions from the GERAS observational study.
    Belger M; Haro JM; Reed C; Happich M; Kahle-Wrobleski K; Argimon JM; Bruno G; Dodel R; Jones RW; Vellas B; Wimo A
    BMC Med Res Methodol; 2016 Jul; 16():83. PubMed ID: 27430559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes.
    Jones RW; Lebrec J; Kahle-Wrobleski K; Dell'Agnello G; Bruno G; Vellas B; Argimon JM; Dodel R; Haro JM; Wimo A; Reed C
    Dement Geriatr Cogn Dis Extra; 2017; 7(1):87-100. PubMed ID: 28611822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of costs of care for patients with Alzheimer's disease.
    Jönsson L; Eriksdotter Jönhagen M; Kilander L; Soininen H; Hallikainen M; Waldemar G; Nygaard H; Andreasen N; Winblad B; Wimo A
    Int J Geriatr Psychiatry; 2006 May; 21(5):449-59. PubMed ID: 16676288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.